Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | NEK2 | P51955 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2331200 | 0.94 | MALT1 (0.42) | MALT1TRPA1TRPV1NEK2HSD11B1 | |
| SCHEMBL3072488 | 0.82 | TRPA1 (0.58) | CNR2MALT1TRPA1TRPV1 | |
| SCHEMBL5236520 | 0.81 | POLB (0.55) | TRPA1GRIA1PDE10ATRPV1 | |
| SCHEMBL18448582 | 0.81 | CLK1 (0.47) | CNR2GRIA1PDE10A | |
| SCHEMBL12813877 | 0.79 | GFER (0.44) | MALT1PDE10A | |
| SCHEMBL4313498 | 0.77 | TRPA1 (0.37) | MALT1TRPA1PDE10ATRPV1 | |
| SCHEMBL19240314 | 0.77 | GFER (0.47) | MALT1PDE10A | |
| SCHEMBL18484147 | 0.77 | ALDH1A1 (0.51) | MALT1 | |
| SCHEMBL3075186 | 0.77 | CNR2 (0.47) | CNR2 | |
| SCHEMBL2641137 | 0.76 | SLC29A1 (0.38) | PDE10ASLC6A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244722-B2 | Amino-substituted 1H-pyrazin-2-ones and 1H-quinoxalin-2-ones | BIOVITRUM AB (SE) | 2007-07-17 | — | — | US | disclosed |
| EP-1534391-B1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| US-20040063693-A1 | Compounds | BIOVITRUM AB (SE) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063693-A1 | Compounds | HTR1A, HTR1B, HTR2C | CNR2 28/4885MALT1 780/4885TRPA1 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.